Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 908 Carboplatin 785 Paclitaxel 739 pembrolizumab 738 Cisplatin 707 Bevacizumab 705 Gemcitabine 619 Docetaxel 578 Rituximab 548 Radiotherapy 539 Dexamethasone 510 Nivolumab 485 Doxorubicin 444 Fluorouracil 392 Capecitabine 376 Etoposide 357 Pemetrexed 334 Cytarabine 334 Oxaliplatin 333 Lenalidomide 327 Prednisone 326 fludarabine phosphate 315 Erlotinib Hydrochloride 314 Trastuzumab 300 Leucovorin 299 fludarabine 296 Vincristine 287 Filgrastim 284 Bortezomib 284 Cetuximab 274

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × elacestrant × Clear all

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡